SCHEMBL2659453

SCHEMBL2659453

CCC#C[CH]c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RELA Q04206 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 1/20 0.34
THPO P40225 1/20 0.34
HIF1A Q16665 1/20 0.34
MTOR P42345 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 4/20 0.33
TP53 P04637 2/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 1/20 0.33
GMNN O75496 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3218909 0.83 TLR8 (0.36) RELANPSR1RAB9AALDH1A1TP53
SCHEMBL2658420 0.79 LMNA (0.38) CYP1A2CYP3A4RAB9AKDM4ELMNA
SCHEMBL7214831 0.77 ALDH1A1 (0.33) CYP1A2ALDH1A1KDM4ELMNATSHR
SCHEMBL3218837 0.77 TRPA1 (0.35) RELACYP1A2CYP3A4ALDH1A1TP53
SCHEMBL2658166 0.73 ALDH1A1 (0.38) RELACYP1A2ALDH1A1LMNATSHR
SCHEMBL27834038 0.72 RELA (0.32) RELAALDH1A1TP53MEN1KMT2A
SCHEMBL9489320 0.71 ALDH1A1 (0.37) RELANPSR1CYP1A2CYP3A4THPO
SCHEMBL8947448 0.69 TSHR (0.48) ALDH1A1KDM4ELMNATSHRSMN1; SMN2
SCHEMBL3218228 0.68 ALDH1A1 (0.33) RELAALDH1A1LMNATSHRMAOB
SCHEMBL43963 0.68 ALDH1A1 (0.33) RELANPSR1CYP3A4THPOHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 EP claimed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 EP claimed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 WO claimed
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 US disclosed
EP-2786985-B1 Antagonists of the glucagon receptor METABASIS THERAPEUTICS INC (US) 2018-11-28 EP disclosed
CN-107669669-A novel glucagon receptor antagonist 症变治疗公司 2018-02-09 CN disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 US disclosed
CN-101610995-B Glucagon receptor antagonists 症变治疗公司 2017-08-08 CN disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 US disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 US disclosed
US-8710236-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2014-04-29 US disclosed
US-20140005385-A1 TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT NIPPON SODA CO., LTD. (JP) 2014-01-02 US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 US disclosed
US-20100137594-A1 TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT NIPPON SODA CO., LTD. (JP) 2010-06-03 US disclosed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 RELA 2071/4885NPSR1 176/4885CYP1A2 2307/4885
US-10239829-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 RELA 1847/4885NPSR1 192/4885CYP1A2 2054/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 RELA 2134/4885NPSR1 176/4885CYP1A2 2272/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 RELA 2134/4885NPSR1 176/4885CYP1A2 2272/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 RELA 2134/4885NPSR1 176/4885CYP1A2 2272/4885
US-20140005385-A1 TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT PAOX, BROX, TTI2 RELA 1283/4885NPSR1 4466/4885CYP1A2 2855/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 RELA 1814/4885NPSR1 191/4885CYP1A2 2016/4885
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A RELA 2673/4885NPSR1 388/4885CYP1A2 1222/4885
US-20100137594-A1 TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT PAOX, H1-10, HAX1 RELA 422/4885NPSR1 3915/4885CYP1A2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.